New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 19, 2012
16:25 EDTLRN, LGND, LOW, DMND, TSN, GSK, INTCOn The Fly: Closing Wrap
Stocks on Wall Street were higher after the averages all advanced sharply at the open and maintained gains through the trading day. Optimism about hopes for a resolution to the fiscal cliff helped push stocks into positive territory Friday and that positive momentum carried over as the new week began. Positive economic data from the National Association of Realtors also buoyed investor confidence on the day... ECONOMIC EVENTS: In the U.S., the National Association of Realtors said that resales of existing homes climbed 2.1% last month to a seasonally adjusted annual rate of 4.79M units, beating forecasts for sales to have declined 0.2% from the prior month. The housing market index for November, a barometer of homebuilder sentiment, rose to 46, versus expectations for a flat 41 reading... COMPANY NEWS: Lowe's (LOW) reported earnings per share with charges that met expectations and revenue that beat consensus, sending shares higher $1.98, or 6.19%, to $33.96... Intel's (INTC) CEO Paul Otellini announced plans to retire in May and shares leveled off after some early day volatility, ending up 6c, or 0.30%, to $20.25... MAJOR MOVERS: Among the notable gainers was Tyson Foods (TSN), advancing $1.84, or 10.90%, to $18.72 after its quarterly earnings beat consensus and the company raised its regular dividend and declared a special dividend. Also higher were shares of Ligan Pharmaceuticals (LGND), up $2.40, or 14.40%, to $19.07 after the company's partner GlaxoSmithKline (GSK) said the FDA approved a new indication for its supportive care treatment for a condition associated with chronic hepatitis C. Among noteworthy losers was (DMND), down $1.79 or 11.83%, to $13.34 after the stock was downgraded to Underperform from Hold at Jeffries. Also lower were shares of K12 (LRN), down $3.84, or 18.78%, to $16.61 following a downgrade to Market Perform at Wells Fargo prompted by issues at one of its schools in Colorado. The company said in a midday release that it has been working "for some time" with Colorado Virtual Academy to address the performance issues that have arisen there... INDICES: The Dow was up 207.65, or 1.65%, to 12,795.96; the Nasdaq was up 62.94, or 2.21%, to 2,916.07; and the S&P 500 was up 27.01, or 1.99%, to 1,386.89.
News For LOW;INTC;TSN;LGND;GSK;DMND;LRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
November 17, 2014
07:35 EDTTSNTyson Foods sees Hillshire acquisition adding $4B in revenues in FY15
The company says "We expect to realize substantial synergies from combining our Prepared Foods business with Hillshire Brands. Synergies are expected to come primarily from operational improvements, purchasing and distribution. As we execute our Prepared Foods strategy, we estimate the impact of the Hillshire Brands synergies, along with the cost savings and the production efficiencies associated with the previously announced plant closures, will positively impact our Prepared Foods segment by more than $225 million in fiscal 2015, and more than $500 million by the third full year of ownership. As we continue to integrate these businesses and deliver the first year synergies, the near-term results for fiscal 2015 are expected to be above the top end of our prior range of 6% despite a projected increase in raw material costs. However, as a result of the improvements we have made in our Prepared Foods business, our acquisition of Hillshire Brands and the significant synergies we expect to realize over the next few years, we believe the long-term profitability of this business should be between 10-12%."
07:35 EDTTSNTyson Foods sees FY15 sales $42B, consensus $42.51B
Subscribe for More Information
07:33 EDTTSNTyson Foods sees FY15 adjusted EPS $3.30-$3.40, consensus $3.33
Subscribe for More Information
07:32 EDTTSNTyson Foods reports Q4 adjusted EPS 87c, consensus 76c
Reports Q4 revenue $10.11B, consensus $10.16B.
05:32 EDTGSKMedidata announces collaboration with GlaxoSmithKline
Medidata (MDSO) announced the completion of a method development project conducted in partnership with GlaxoSmithKline (GSK) to evaluate the impact of unifying mobile health, or mHealth, devices with cloud-based technologies in a clinical trial setting. The joint initiative assessed the capabilities of mHealth tools and evaluated how they could be used to enable a new model for clinical trial conduct that aligns site and patient needs with faster study execution and reduced costs. The collaborative project, which took place at GSK’s Human Performance Lab, demonstrated that mHealth technologies have the power to comprehensively collect large volumes of objective data that is reliable, secure and analysis-ready, and provides real-time, continuous insight into the well being of patients. All of the data collected was audited and is compliant with FDA regulations. Additionally, the effort indicated that mobile devices can support the long-term goal of lessening the burden on patients participating in studies by streamlining routine procedures, eliminating unnecessary ones and reducing visits to clinical trial sites.
November 14, 2014
17:21 EDTLGNDLigand to host analyst day
Analyst Day to be held in New York on November 18 at 10 am. Webcast Link
14:53 EDTGSKCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
07:14 EDTGSKAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
12:59 EDTGSKApollo plans bid for GSK mature drugs business, Reuters reports
Subscribe for More Information
10:01 EDTTSNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:44 EDTTSNTyson Foods initiated with an Outperform at RBC Capital
Target $48.
November 12, 2014
15:08 EDTINTCEarnings Preview: Cisco reports amid analyst debate on break-up potential
Subscribe for More Information
14:08 EDTINTCIntel reports 427.7K share position in Rocket Fuel
Subscribe for More Information
09:16 EDTGSK, LGNDLigand reports GlaxoSmithKline EU regulatory submission for Revolade
Subscribe for More Information
08:53 EDTGSKGlaxoSmithKline weakness creates buying opportunity, says Argus
After GlaxoSmithKline cut its near-term EPS guidance, Argus still believes that the company's deals with Novartis (NVS) should boost its EPS growth in the years ahead, likely as soon as 2015. The firm thinks the stock is a good value for long-term investors, and it keeps a Buy rating on the shares.
08:18 EDTGSKUBS to hold a conference
Subscribe for More Information
06:53 EDTTSNTyson Foods volatility elevated into Q4 and outlook
Subscribe for More Information
November 11, 2014
12:37 EDTLOWLowe's November volatility elevated into Q3 and outlook
Lowe's November call option implied volatility is at 28, December is at 22, January and April is at 18; compared to its 26-week average of 22 according to Track Data, suggesting large near term price movement into the expected release of Q3 results on November 19.
November 10, 2014
16:07 EDTGSKUBS to hold a conference
UBS European Conference is being held in London, England on November 11-12.
12:09 EDTTSNUSDA raises 2014 meat production forecast, lowers 2015
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use